$5.25 EPS Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter

Brokerages expect that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will report $5.25 earnings per share (EPS) for the current quarter, Zacks reports. Eight analysts have made estimates for Regeneron Pharmaceuticals’ earnings. The lowest EPS estimate is $4.44 and the highest is $5.93. Regeneron Pharmaceuticals reported earnings per share of $3.99 in the same quarter last year, which would suggest a positive year-over-year growth rate of 31.6%. The firm is expected to announce its next earnings report on Wednesday, November 14th.

On average, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $20.30 per share for the current fiscal year, with EPS estimates ranging from $18.20 to $21.95. For the next year, analysts forecast that the firm will report earnings of $21.87 per share, with EPS estimates ranging from $19.08 to $25.65. Zacks’ earnings per share averages are an average based on a survey of analysts that cover Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 earnings per share for the quarter, beating the consensus estimate of $4.60 by $0.85. The firm had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.56 billion. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.17 EPS.

Several analysts have weighed in on REGN shares. Canaccord Genuity reaffirmed a “$367.74” rating and set a $304.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, July 19th. TheStreet raised Regeneron Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, July 25th. Credit Suisse Group set a $420.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, April 27th. Leerink Swann set a $435.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, May 4th. Finally, BidaskClub raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 10th. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $416.52.

Regeneron Pharmaceuticals traded down $3.36, hitting $368.78, during mid-day trading on Tuesday, Marketbeat.com reports. 623,873 shares of the company’s stock traded hands, compared to its average volume of 863,708. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.62 and a quick ratio of 2.92. The company has a market capitalization of $40.21 billion, a P/E ratio of 27.50, a PEG ratio of 1.29 and a beta of 1.26. Regeneron Pharmaceuticals has a one year low of $281.89 and a one year high of $505.49.

In related news, major shareholder Sanofi sold 121,601 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, June 8th. The stock was sold at an average price of $309.31, for a total value of $37,612,405.31. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $380.00, for a total value of $760,000.00. Following the completion of the transaction, the director now owns 14,000 shares in the company, valued at $5,320,000. The disclosure for this sale can be found here. Insiders sold a total of 286,388 shares of company stock worth $94,373,982 in the last three months. Company insiders own 12.42% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ostrum Asset Management acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $108,000. Summit Trail Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 22,971.8% in the 1st quarter. Summit Trail Advisors LLC now owns 166,348 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 165,627 shares during the last quarter. Financial Gravity Wealth Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $211,000. Sawtooth Solutions LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $218,000. Finally, Greenleaf Trust acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $231,000. Institutional investors and hedge funds own 65.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply